Genetics of Cancer

This test detects mutations in 74 genes associated with 23 different types of cancer in women, including breast cancer, ovarian cancer, colorectal cancer, endometrial cancer, gastric cancer, kidney cancer, thyroid cancer, parathyroid cancer, multiple endocrine adenomas, neurofibromatosis, pheochromocytosis, bladder cancer, ureteral cancer, familial paraganglioma, retinoblastoma, melanoma, multiple osteochondroma, gastrointestinal tumors, hereditary neuroblastoma, tuberous sclerosis, hereditary nephroblastoma. 

Genetic testing for hereditary and somatic cancers is the basis for proper diagnosis and treatment in affected patients. They are also indispensable in the early prevention of their relatives, who are carriers of genetic mutations associated with the risk of developing cancer. We can guide doctors in choosing the right therapeutic options with the help of genetic tests for detecting and preventing cancer.

GENICA Lab analyses a wide range of genetic variants, enabling early prevention, cancer diagnosis, prognosis, treatment choice and post-therapeutic monitoring of the patient.

The test detects mutations in 79 genes associated with 23 different types of cancer in men, including breast cancer, colorectal cancer, prostate cancer, stomach cancer, kidney cancer, thyroid cancer, parathyroid cancer, multiple endocrine adenomas, neurofibromatosis, pheochromocytosis, bladder cancer, ureteral cancer, familial paraganglioma, retinoblastoma, melanoma, multiple osteochondroma, gastrointestinal tumors, hereditary neuroblastoma, tuberous sclerosis, hereditary nephroblastoma. 

Genetic testing for hereditary and somatic cancers is the basis for proper diagnosis and treatment in affected patients. They are also indispensable in the early prevention of their relatives, who are carriers of genetic mutations associated with the risk of developing cancer. We can guide doctors in choosing the right therapeutic options with the help of genetic tests for detecting and preventing cancer.

GENICA Lab analyses a wide range of genetic variants, enabling early prevention, cancer diagnosis, prognosis, treatment choice and post-therapeutic monitoring of the patient.

 Cervical cancer is the second most common cancer globally among women between the ages of 20 and 55. It is caused by the human papillomavirus (HPV). Cervical cancer is the final stage of untreated HPV infection, characterized by the continuing presence of HPV and detected by repeated DNA testing of cervical samples. HPV infection is primarily sexually transmitted and usually occurs without clinical signs or symptoms.

The process from HPV infection to cancer is slow. This makes the initiating infections and the pre-disease lesions treatable with regular prophylaxis, thus preventing the development of cervical cancer.

Up to 93% of cervical cancers are preventable with GENICA’s diagnostic solutions. READ MORE

This test detects mutations in 26 genes associated with breast cancer and ovarian cancer.

A group of DNA tests associated with gynecologic cancers, including cervical cancer (SEE MORE), endometrial cancer, ovarian cancer, breast cancer.

This test detects mutations in the two main genes associated with breast cancer and ovarian cancer.

The pharmacogenetics of cancer identifies patients at risk of severe toxicity or those who are likely to benefit from a particular treatment. Thus, it helps to design individualized cancer therapy. 

There are significant differences between the pharmacogenomics of cancer and other diseases.

This test detects mutations in 12 genes associated with pancreatic cancer.

This test detects mutations in 23 genes associated with colon cancer.

This test detects mutations in 23 genes associated with prostate cancer.

The pharmacogenetics of cancer identifies patients at risk of severe toxicity or those who are likely to benefit from a particular treatment. Thus, it helps to design individualized cancer therapy. There are significant differences between the pharmacogenomics of cancer and other diseases.

 This test detects mutations in 20,000 genes associated with various hereditary conditions. It analyzes packages of target genes associated with specific conditions according to clinical diagnosis (Cancer Panel, Pediatric Panel, Diabetes Panel, Epilepsy Panel, Intellectual Deficiency/Autism Panel, Skeletal Dysplasias Panel, Cardiomyopathies Panel, etc.). 

This test detects mutations in the MEN1 gene associated with MEN1 multiple endocrine neoplasia.

This test detects mutations in the RET gene associated with MEN2 multiple endocrine neoplasia.

This test detects mutations in the VHL gene associated with von Hipple-Lindau syndrome.